The purpose of this study is to demonstrate the antihypertensive efficacy of once daily oral administration of ACT 280778 on DBP compared to placebo after 28 days.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
196
10 mg once daily for 28 ± 2 days
Placebo oral capsules matching ACT-280778
10 mg once daily for 28 ± 2 days
Clinical Investigative Site 4000
Afula, Israel
Clinical Investigative Site 1003
Ashkelon, Israel
Change in mean(c) trough(d) SiDBP
Change from baseline(b) to Day 28 (± 2 days) of Period 2 (Visit 7)in mean(c) trough(d) SiDBP.
Time frame: Baseline to day 28
Change in mean trough SiSBP.
Change from baseline to Day 28 (± 2 days) of Period 2 (Visit 7) in mean trough SiSBP.
Time frame: Baseline to Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Investigative Site 1008
Beersheba, Israel
Clinical Investigative Site 1004
Giv‘atayim, Israel
Clinical Investigative Site 1009
Holon, Israel
Clinical Investigative Site 1000
Jerusalem, Israel
Clinical Investigative Site 1006
Nazareth, Israel
Clinical Investigative Site 1007
Nazareth, Israel
Clinical Investigative Site 1005
Safed, Israel
Clinical Investigative Site 1010
Tel Aviv, Israel
...and 8 more locations